Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, 367-369 [05-3]
Download as PDF
<![CDATA[
367
Federal Register / Vol. 70, No. 2 / Tuesday, January 4, 2005 / Notices
their rights to the petition to Ancore
Corp., FDA published in the Federal
Register of December 21, 2004, a
document that amended 21 CFR 179.21
to provide for the use of sources of
monoenergetic neutrons to inspect cargo
containers that may contain food. Under
this regulation, monoenergetic neutron
sources producing neutrons at energies
not less than 1 million electron volts
(MeV) but no greater than 14 MeV may
be used for inspection of cargo
containers that may contain food,
providing that the neutron source bears
a label stating the minimum and
maximum energy of radiation emitted
by the source. The regulation also
requires that the label or accompanying
labeling bear adequate directions for
safe use and a statement that no food
shall be exposed to this radiation source
so as to receive a dose in excess of 0.01
gray. FDA has determined that this
information is needed to assure safe use
of the source of radiation.
FDA estimates the total annual
burden for this collection of information
as follows:
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
21 CFR Section
179.21(a)(5),
(b)(1)(iv), and
(b)(2)(v)
1 There
No. of Respondents
Annual Frequency
per Response
1
1
1
Hours per Response
1
Total Operating &
Maintenance
Costs
$100
Total Hours
1
are no capital costs associated with this collection of information.
FDA estimates that the burden will be
insignificant because the reporting
requirement reflects customary business
practice. Based on discussions with an
industry representative, the burden
hours estimated for this collection of
information is 1 hour. The operating
and maintenance cost associated with
this collection is $100 for preparation of
labels.
Dated: December 28, 2004.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05–29 Filed 1–3–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of Laboratories Which
Meet Minimum Standards To Engage in
Urine Drug Testing for Federal
Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
AGENCY:
ACTION:
Total Annual Responses
Notice.
SUMMARY: The Department of Health and
Human Services (HHS) notifies Federal
agencies of the laboratories currently
certified to meet the standards of
Subpart C of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908),
on September 30, 1997 (62 FR 51118),
and on April 13, 2004 (69 FR 19644).
VerDate jul<14>2003
18:02 Jan 03, 2005
Jkt 205001
A notice listing all currently certified
laboratories is published in the Federal
Register during the first week of each
month. If any laboratory’s certification
is suspended or revoked, the laboratory
will be omitted from subsequent lists
until such time as it is restored to full
certification under the Mandatory
Guidelines.
If any laboratory has withdrawn from
the HHS National Laboratory
Certification Program (NLCP) during the
past month, it will be listed at the end,
and will be omitted from the monthly
listing thereafter.
This notice is also available on the
Internet at https://workplace.samhsa.gov
and https://www.drugfreeworkplace.gov.
FOR FURTHER INFORMATION CONTACT: Mrs.
Giselle Hersh or Dr. Walter Vogl,
Division of Workplace Programs,
SAMHSA/CSAP, Room 2–1035, 1 Choke
Cherry Road, Rockville, Maryland
20857; 240–276–2600 (voice), 240–276–
2610 (fax).
SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were developed
in accordance with Executive Order
12564 and section 503 of Public Law
100–71. Subpart C of the Mandatory
Guidelines, ‘‘Certification of
Laboratories Engaged in Urine Drug
Testing for Federal Agencies,’’ sets strict
standards that laboratories must meet in
order to conduct drug and specimen
validity tests on urine specimens for
Federal agencies. To become certified,
an applicant laboratory must undergo
three rounds of performance testing plus
an on-site inspection. To maintain that
certification, a laboratory must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories which claim to be in the
applicant stage of certification are not to
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A laboratory
must have its letter of certification from
HHS/SAMHSA (formerly: HHS/NIDA)
which attests that it has met minimum
standards.
In accordance with Subpart C of the
Mandatory Guidelines dated April 13,
2004 (69 FR 19644), the following
laboratories meet the minimum
standards to conduct drug and specimen
validity tests on urine specimens:
ACL Laboratories, 8901 W. Lincoln
Ave., West Allis, WI 53227, 414–328–
7840/800–877–7016 (Formerly:
Bayshore Clinical Laboratory);
ACM Medical Laboratory, Inc., 160
Elmgrove Park, Rochester, NY 14624,
585–429–2264;
Advanced Toxicology Network, 3560
Air Center Cove, Suite 101, Memphis,
TN 38118, 901–794–5770/888–290–
1150;
Aegis Analytical Laboratories, Inc.,
345 Hill Ave., Nashville, TN 37210,
615–255–2400;
Baptist Medical Center-Toxicology
Laboratory, 9601 I–630, Exit 7, Little
Rock, AR 72205–7299, 501–202–2783
(Formerly: Forensic Toxicology
Laboratory Baptist Medical Center);
Clinical Reference Lab, 8433 Quivira
Rd., Lenexa, KS 66215–2802, 800–445–
6917;
Diagnostic Services Inc., dba DSI,
12700 Westlinks Dr., Fort Myers, FL
33913, 239–561–8200/800–735–5416;
Doctors Laboratory, Inc., 2906 Julia
Drive, Valdosta, GA 31602, 229–671–
2281;
DrugProof, Division of Dynacare/
Laboratory of Pathology, LLC, 1229
Madison St., Suite 500, Nordstrom
Medical Tower, Seattle, WA 98104,
206–386–2661/800–898–0180
(Formerly: Laboratory of Pathology of
E:\FR\FM\04JAN1.SGM
04JAN1
368
Federal Register / Vol. 70, No. 2 / Tuesday, January 4, 2005 / Notices
Seattle, Inc., DrugProof, Division of
Laboratory of Pathology of Seattle, Inc.);
DrugScan, Inc., P.O. Box 2969, 1119
Mearns Rd., Warminster, PA 18974,
215–674–9310;
Dynacare Kasper Medical
Laboratories*, 10150–102 St., Suite 200,
Edmonton, Alberta, Canada T5J 5E2,
780–451–3702 / 800–661–9876;
ElSohly Laboratories, Inc., 5
Industrial Park Dr., Oxford, MS 38655,
662–236–2609;
Express Analytical Labs, 3405 7th
Ave., Suite 106, Marion, IA 52302, 319–
377–0500;
General Medical Laboratories, 36
South Brooks St., Madison, WI 53715,
608–267–6225;
Kroll Laboratory Specialists, Inc.,
1111 Newton St., Gretna, LA 70053,
504–361–8989/800–433–3823
(Formerly: Laboratory Specialists, Inc.);
LabOne, Inc., 10101 Renner Blvd.,
Lenexa, KS 66219, 913–888–3927/800–
873–8845 (Formerly: Center for
Laboratory Services, a Division of
LabOne, Inc.);
LabOne, Inc., d/b/a Northwest
Toxicology, 1141 E. 3900 S., Salt Lake
City, UT 84124, 801–293–2300/800–
322–3361 (Formerly: NWT Drug
Testing, NorthWest Toxicology, Inc.;
Northwest Drug Testing, a division of
NWT Inc.);
Laboratory Corporation of America
Holdings, 7207 N. Gessner Rd.,
Houston, TX 77040, 713–856–8288/
800–800–2387;
Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869, 908–526–2400/800–437–4986
(Formerly: Roche Biomedical
Laboratories, Inc.);
Laboratory Corporation of America
Holdings, 1904 Alexander Dr., Research
Triangle Park, NC 27709, 919–572–
6900/800–833–3984 (Formerly: LabCorp
Occupational Testing Services, Inc.,
CompuChem Laboratories, Inc.;
CompuChem Laboratories, Inc., A
Subsidiary of Roche Biomedical
Laboratory; Roche CompuChem
Laboratories, Inc., A Member of the
Roche Group);
Laboratory Corporation of America
Holdings, 10788 Roselle St., San Diego,
CA 92121, 800–882–7272 (Formerly:
Poisonlab, Inc.);
Laboratory Corporation of America
Holdings, 1120 Main Street, Southaven,
MS 38671, 866–827–8042/800–233–
6339 (Formerly: LabCorp Occupational
Testing Services, Inc.; MedExpress/
National Laboratory Center);
Marshfield Laboratories, Forensic
Toxicology Laboratory, 1000 North Oak
Ave., Marshfield, WI 54449, 715–389–
3734/800–331–3734;
VerDate jul<14>2003
18:02 Jan 03, 2005
Jkt 205001
MAXXAM Analytics Inc.*, 6740
Campobello Road, Mississauga, ON,
Canada L5N 2L8, 905–817–5700
(Formerly: NOVAMANN (Ontario) Inc.);
MedTox Laboratories, Inc., 402 W.
County Rd. D, St. Paul, MN 55112, 651–
636–7466/800–832–3244;
MetroLab-Legacy Laboratory Services,
1225 NE 2nd Ave., Portland, OR 97232,
503–413–5295/800–950–5295;
Minneapolis Veterans Affairs Medical
Center, Forensic Toxicology Laboratory,
1 Veterans Dr., Minneapolis, MN 55417,
612–725–2088;
National Toxicology Laboratories,
Inc., 1100 California Ave., Bakersfield,
CA 93304, 661–322–4250/800–350–
3515;
One Source Toxicology Laboratory,
Inc., 1213 Genoa-Red Bluff, Pasadena,
TX 77504, 888–747–3774 (Formerly:
University of Texas Medical Branch,
Clinical Chemistry Division; UTMB
Pathology-Toxicology Laboratory);
Oregon Medical Laboratories, P.O.
Box 972, 722 East 11th Ave., Eugene,
OR 97440–0972, 541–687–2134;
Pacific Toxicology Laboratories, 9348
DeSoto Ave., Chatsworth, CA 91311,
800–328–6942 (Formerly: Centinela
Hospital Airport Toxicology
Laboratory);
Pathology Associates Medical
Laboratories, 110 West Cliff Dr.,
Spokane, WA 99204, 509–755–8991/
800–541–7897x7;
Physicians Reference Laboratory,
7800 West 110th St., Overland Park, KS
66210, 913–339–0372/800–821–3627;
Quest Diagnostics Incorporated, 3175
Presidential Dr., Atlanta, GA 30340,
770–452–1590/800–729–6432
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline BioScience Laboratories);
Quest Diagnostics Incorporated, 4770
Regent Blvd., Irving, TX 75063, 800–
824–6152 (Moved from the Dallas
location on 03/31/01; Formerly:
SmithKline Beecham Clinical
Laboratories; SmithKline Bio-Science
Laboratories);
Quest Diagnostics Incorporated, 4230
South Burnham Ave., Suite 250, Las
Vegas, NV 89119–5412, 702–733–7866/
800–433–2750 (Formerly: Associated
Pathologists Laboratories, Inc.);
Quest Diagnostics Incorporated, 400
Egypt Rd., Norristown, PA 19403, 610–
631–4600/877–642–2216 (Formerly:
SmithKline Beecham Clinical
Laboratories; SmithKline Bio-Science
Laboratories);
Quest Diagnostics Incorporated, 506
E. State Pkwy., Schaumburg, IL 60173,
800–669–6995/847–885–2010
(Formerly: SmithKline Beecham
Clinical Laboratories; International
Toxicology Laboratories);
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
Quest Diagnostics Incorporated, 7600
Tyrone Ave., Van Nuys, CA 91405, 818–
989–2520/800–877–2520 (Formerly:
SmithKline Beecham Clinical
Laboratories);
Scientific Testing Laboratories, Inc.,
450 Southlake Blvd., Richmond, VA
23236, 804–378–9130;
Sciteck Clinical Laboratories, Inc., 317
Rutledge Rd., Fletcher, NC 28732, 828–
650–0409;
S.E.D. Medical Laboratories, 5601
Office Blvd., Albuquerque, NM 87109,
505–727–6300/800–999–5227.
South Bend Medical Foundation, Inc.,
530 N. Lafayette Blvd., South Bend, IN
46601, 574–234–4176 x276;
Southwest Laboratories, 4645 E.
Cotton Center Boulevard, Suite 177,
Phoenix, AZ 85040, 602–438–8507/800–
279–0027;
Sparrow Health System, Toxicology
Testing Center, St. Lawrence Campus,
1210 W. Saginaw, Lansing, MI 48915,
517–364–7400 (Formerly: St. Lawrence
Hospital & Healthcare System);
St. Anthony Hospital Toxicology
Laboratory, 1000 N. Lee St., Oklahoma
City, OK 73101, 405–272–7052;
Toxicology & Drug Monitoring
Laboratory, University of Missouri
Hospital & Clinics, 301 Business Loop
70 West, Suite 208, Columbia, MO
65203, 573–882–1273;
Toxicology Testing Service, Inc., 5426
NW., 79th Ave., Miami, FL 33166, 305–
593–2260;
U.S. Army Forensic Toxicology Drug
Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755–5235,
301–677–7085;
* The Standards Council of Canada
(SCC) voted to end its Laboratory
Accreditation Program for Substance
Abuse (LAPSA) effective May 12, 1998.
Laboratories certified through that
program were accredited to conduct
forensic urine drug testing as required
by U.S. Department of Transportation
(DOT) regulations. As of that date, the
certification of those accredited
Canadian laboratories will continue
under DOT authority. The responsibility
for conducting quarterly performance
testing plus periodic on-site inspections
of those LAPSA-accredited laboratories
was transferred to the U.S. HHS, with
the HHS’ NLCP contractor continuing to
have an active role in the performance
testing and laboratory inspection
processes. Other Canadian laboratories
wishing to be considered for the NLCP
may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to
be qualified, HHS will recommend that
DOT certify the laboratory (Federal
Register, July 16, 1996) as meeting the
minimum standards of the Mandatory
E:\FR\FM\04JAN1.SGM
04JAN1
369
Federal Register / Vol. 70, No. 2 / Tuesday, January 4, 2005 / Notices
Guidelines published in the Federal
Register on April 13, 2004 (69 FR
19644). After receiving DOT
certification, the laboratory will be
included in the monthly list of HHS
certified laboratories and participate in
the NLCP certification maintenance
program.
Pat Bransford,
Acting Executive Officer, SAMHSA.
[FR Doc. 05–3 Filed 1–3–05; 8:45 am]
BILLING CODE 4160–20–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Notice of SAMHSA’s Ceasing
Publication of Notices of Funding
Availability (NOFAs) and Requests for
Applications (RFAs) in the Federal
Register
Consistent with the
Department of Health and Human
Services management objectives, the
Substance Abuse and Mental Health
Services Administration (SAMHSA)
announces a change in its practice of
publishing notices of grant funding
availability in the Federal Register.
Rather than continue publishing NOFAs
and RFAs in the Federal Register,
SAMHSA will instead post notices of
funding availability only on https://
www.Grants.gov and https://
www.samhsa.gov. Only single source or
limited competition announcements
will continue to be published in the
Federal Register. This change will be
effective January 3, 2005.
Applicants should be aware that all
the necessary information to apply for
grant funds will continue to be available
at SAMHSA’s two national
clearinghouses: The National
Clearinghouse for Alcohol and Drug
SUMMARY:
Information (NCADI)—1–800–729–
6686—for substance abuse prevention or
treatment grants; and the National
Mental Health Information Center—1–
800–789–CMHS (2647)—for mental
health grants.
FOR FURTHER INFORMATION CONTACT:
Cathy J. Friedman, M.A., SAMHSA, 1
Choke Cherry Road, Room 8–1097,
Rockville, MD 20857; phone (240) 276–
2316; E-mail:
cathy.friedman@samhsa.hhs.gov.
Dated: December 28, 2004.
Daryl Kade,
Director, Office of Policy, Planning and
Budget, Substance Abuse and Mental Health
Services Administration.
[FR Doc. 05–34 Filed 1–3–05; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HOMELAND
SECURITY
stakeholders of the National Fire
Programs (NFP), a part of the United
States Fire Administration (USFA).
SUPPLEMENTARY INFORMATION: As an
entity of the U.S. Department of
Homeland Security/Federal Emergency
Management Agency (FEMA), the
mission of the USFA is to reduce life
and economic losses due to fire and
related hazards. The NFP, within the
USFA, oversees the development of
campaigns, products, services,
curriculum and doctrine for leadership
development training and educational
courses. These programs are designed to
increase the capacity and
interoperability of the fire and
emergency services on prevention,
mitigation, and response to local
emergencies and preparedness for
consequences of day-to-day and larger
scale disasters.
Collection of Information
Federal Emergency Management
Agency
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Federal Emergency
Management Agency, Emergency
Preparedness and Response Directorate,
U.S. Department of Homeland Security.
ACTION: Notice and request for
comments.
AGENCY:
SUMMARY: The Federal Emergency
Management Agency, as part of its
continuing effort to reduce paperwork
and respondent burden, invites the
general public and other Federal
agencies to take this opportunity to
comment on proposed new information
collections. In accordance with the
Paperwork Reduction Act of 1995 (44
U.S.C. 3506(c)(2)(A)), this notice seeks
comments concerning the need to
collect program information from
Title: National Fire Programs (NFP)
Stakeholders Interview.
Type of Information Collection: New
collection.
OMB Number: 1660–NEW14.
Form Numbers: None.
Abstract: Consistent with
performance-based management
practices, the NFP is developing a
comprehensive Strategic Business and
Implementation Plan. This information
collection will capture stakeholders’
perspective critical to the NFP’s ability
to plan effectively and deliver demanddriven products and services. Data
findings will be used to: (1) Support the
development of the Strategic Business
and Implementation Plan, and (2) set
customer service standards.
Affected Public: State, local and
Tribal governments, and Not-for-Profit
Institutions.
Estimated Total Annual Burden
Hours: 50 hours.
ANNUAL BURDEN HOURS
Number of
respondents
Frequency of
responses
Burden hours
per
respondent
Annual
responses
Total annual
burden hours
(A)
Project/activity (survey form(s), focus group, etc.)
(B)
(C)
(AxB )
(AxBxC)
Stakeholders’ Interviews ......................................................
50
1
1
50
50
Total ..........................................................................
50
1
1
50
50
Estimated Cost: $23 per response/
interview.
Comments: Written comments are
solicited to (a) Evaluate whether the
proposed data collection is necessary for
the proper performance of the agency,
VerDate jul<14>2003
18:02 Jan 03, 2005
Jkt 205001
including whether the information shall
have practical utility; (b) evaluate the
accuracy of the agency’s estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
(c) enhance the quality, utility, and
clarity of the information to be
collected; and (d) minimize the burden
of the collection of information on those
who are to respond, including through
the use of appropriate automated,
E:\FR\FM\04JAN1.SGM
04JAN1
]]>Agencies
[Federal Register Volume 70, Number 2 (Tuesday, January 4, 2005)]
[Notices]
[Pages 367-369]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-3]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Current List of Laboratories Which Meet Minimum Standards To
Engage in Urine Drug Testing for Federal Agencies
AGENCY: Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services (HHS) notifies
Federal agencies of the laboratories currently certified to meet the
standards of Subpart C of the Mandatory Guidelines for Federal
Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory
Guidelines were first published in the Federal Register on April 11,
1988 (53 FR 11970), and subsequently revised in the Federal Register on
June 9, 1994 (59 FR 29908), on September 30, 1997 (62 FR 51118), and on
April 13, 2004 (69 FR 19644).
A notice listing all currently certified laboratories is published
in the Federal Register during the first week of each month. If any
laboratory's certification is suspended or revoked, the laboratory will
be omitted from subsequent lists until such time as it is restored to
full certification under the Mandatory Guidelines.
If any laboratory has withdrawn from the HHS National Laboratory
Certification Program (NLCP) during the past month, it will be listed
at the end, and will be omitted from the monthly listing thereafter.
This notice is also available on the Internet at https://
workplace.samhsa.gov and https://www.drugfreeworkplace.gov.
FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh or Dr. Walter Vogl,
Division of Workplace Programs, SAMHSA/CSAP, Room 2-1035, 1 Choke
Cherry Road, Rockville, Maryland 20857; 240-276-2600 (voice), 240-276-
2610 (fax).
SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were developed in
accordance with Executive Order 12564 and section 503 of Public Law
100-71. Subpart C of the Mandatory Guidelines, ``Certification of
Laboratories Engaged in Urine Drug Testing for Federal Agencies,'' sets
strict standards that laboratories must meet in order to conduct drug
and specimen validity tests on urine specimens for Federal agencies. To
become certified, an applicant laboratory must undergo three rounds of
performance testing plus an on-site inspection. To maintain that
certification, a laboratory must participate in a quarterly performance
testing program plus undergo periodic, on-site inspections.
Laboratories which claim to be in the applicant stage of
certification are not to be considered as meeting the minimum
requirements described in the HHS Mandatory Guidelines. A laboratory
must have its letter of certification from HHS/SAMHSA (formerly: HHS/
NIDA) which attests that it has met minimum standards.
In accordance with Subpart C of the Mandatory Guidelines dated
April 13, 2004 (69 FR 19644), the following laboratories meet the
minimum standards to conduct drug and specimen validity tests on urine
specimens:
ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414-
328-7840/800-877-7016 (Formerly: Bayshore Clinical Laboratory);
ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY
14624, 585-429-2264;
Advanced Toxicology Network, 3560 Air Center Cove, Suite 101,
Memphis, TN 38118, 901-794-5770/888-290-1150;
Aegis Analytical Laboratories, Inc., 345 Hill Ave., Nashville, TN
37210, 615-255-2400;
Baptist Medical Center-Toxicology Laboratory, 9601 I-630, Exit 7,
Little Rock, AR 72205-7299, 501-202-2783 (Formerly: Forensic Toxicology
Laboratory Baptist Medical Center);
Clinical Reference Lab, 8433 Quivira Rd., Lenexa, KS 66215-2802,
800-445-6917;
Diagnostic Services Inc., dba DSI, 12700 Westlinks Dr., Fort Myers,
FL 33913, 239-561-8200/800-735-5416;
Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602,
229-671-2281;
DrugProof, Division of Dynacare/Laboratory of Pathology, LLC, 1229
Madison St., Suite 500, Nordstrom Medical Tower, Seattle, WA 98104,
206-386-2661/800-898-0180 (Formerly: Laboratory of Pathology of
[[Page 368]]
Seattle, Inc., DrugProof, Division of Laboratory of Pathology of
Seattle, Inc.);
DrugScan, Inc., P.O. Box 2969, 1119 Mearns Rd., Warminster, PA
18974, 215-674-9310;
Dynacare Kasper Medical Laboratories*, 10150-102 St., Suite 200,
Edmonton, Alberta, Canada T5J 5E2, 780-451-3702 / 800-661-9876;
ElSohly Laboratories, Inc., 5 Industrial Park Dr., Oxford, MS
38655, 662-236-2609;
Express Analytical Labs, 3405 7th Ave., Suite 106, Marion, IA
52302, 319-377-0500;
General Medical Laboratories, 36 South Brooks St., Madison, WI
53715, 608-267-6225;
Kroll Laboratory Specialists, Inc., 1111 Newton St., Gretna, LA
70053, 504-361-8989/800-433-3823 (Formerly: Laboratory Specialists,
Inc.);
LabOne, Inc., 10101 Renner Blvd., Lenexa, KS 66219, 913-888-3927/
800-873-8845 (Formerly: Center for Laboratory Services, a Division of
LabOne, Inc.);
LabOne, Inc., d/b/a Northwest Toxicology, 1141 E. 3900 S., Salt
Lake City, UT 84124, 801-293-2300/800-322-3361 (Formerly: NWT Drug
Testing, NorthWest Toxicology, Inc.; Northwest Drug Testing, a division
of NWT Inc.);
Laboratory Corporation of America Holdings, 7207 N. Gessner Rd.,
Houston, TX 77040, 713-856-8288/800-800-2387;
Laboratory Corporation of America Holdings, 69 First Ave., Raritan,
NJ 08869, 908-526-2400/800-437-4986 (Formerly: Roche Biomedical
Laboratories, Inc.);
Laboratory Corporation of America Holdings, 1904 Alexander Dr.,
Research Triangle Park, NC 27709, 919-572-6900/800-833-3984 (Formerly:
LabCorp Occupational Testing Services, Inc., CompuChem Laboratories,
Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical
Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche
Group);
Laboratory Corporation of America Holdings, 10788 Roselle St., San
Diego, CA 92121, 800-882-7272 (Formerly: Poisonlab, Inc.);
Laboratory Corporation of America Holdings, 1120 Main Street,
Southaven, MS 38671, 866-827-8042/800-233-6339 (Formerly: LabCorp
Occupational Testing Services, Inc.; MedExpress/National Laboratory
Center);
Marshfield Laboratories, Forensic Toxicology Laboratory, 1000 North
Oak Ave., Marshfield, WI 54449, 715-389-3734/800-331-3734;
MAXXAM Analytics Inc.*, 6740 Campobello Road, Mississauga, ON,
Canada L5N 2L8, 905-817-5700 (Formerly: NOVAMANN (Ontario) Inc.);
MedTox Laboratories, Inc., 402 W. County Rd. D, St. Paul, MN 55112,
651-636-7466/800-832-3244;
MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR
97232, 503-413-5295/800-950-5295;
Minneapolis Veterans Affairs Medical Center, Forensic Toxicology
Laboratory, 1 Veterans Dr., Minneapolis, MN 55417, 612-725-2088;
National Toxicology Laboratories, Inc., 1100 California Ave.,
Bakersfield, CA 93304, 661-322-4250/800-350-3515;
One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff,
Pasadena, TX 77504, 888-747-3774 (Formerly: University of Texas Medical
Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology
Laboratory);
Oregon Medical Laboratories, P.O. Box 972, 722 East 11th Ave.,
Eugene, OR 97440-0972, 541-687-2134;
Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA
91311, 800-328-6942 (Formerly: Centinela Hospital Airport Toxicology
Laboratory);
Pathology Associates Medical Laboratories, 110 West Cliff Dr.,
Spokane, WA 99204, 509-755-8991/800-541-7897x7;
Physicians Reference Laboratory, 7800 West 110th St., Overland
Park, KS 66210, 913-339-0372/800-821-3627;
Quest Diagnostics Incorporated, 3175 Presidential Dr., Atlanta, GA
30340, 770-452-1590/800-729-6432 (Formerly: SmithKline Beecham Clinical
Laboratories; SmithKline Bio-Science Laboratories);
Quest Diagnostics Incorporated, 4770 Regent Blvd., Irving, TX
75063, 800-824-6152 (Moved from the Dallas location on 03/31/01;
Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-
Science Laboratories);
Quest Diagnostics Incorporated, 4230 South Burnham Ave., Suite 250,
Las Vegas, NV 89119-5412, 702-733-7866/800-433-2750 (Formerly:
Associated Pathologists Laboratories, Inc.);
Quest Diagnostics Incorporated, 400 Egypt Rd., Norristown, PA
19403, 610-631-4600/877-642-2216 (Formerly: SmithKline Beecham Clinical
Laboratories; SmithKline Bio-Science Laboratories);
Quest Diagnostics Incorporated, 506 E. State Pkwy., Schaumburg, IL
60173, 800-669-6995/847-885-2010 (Formerly: SmithKline Beecham Clinical
Laboratories; International Toxicology Laboratories);
Quest Diagnostics Incorporated, 7600 Tyrone Ave., Van Nuys, CA
91405, 818-989-2520/800-877-2520 (Formerly: SmithKline Beecham Clinical
Laboratories);
Scientific Testing Laboratories, Inc., 450 Southlake Blvd.,
Richmond, VA 23236, 804-378-9130;
Sciteck Clinical Laboratories, Inc., 317 Rutledge Rd., Fletcher, NC
28732, 828-650-0409;
S.E.D. Medical Laboratories, 5601 Office Blvd., Albuquerque, NM
87109, 505-727-6300/800-999-5227.
South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South
Bend, IN 46601, 574-234-4176 x276;
Southwest Laboratories, 4645 E. Cotton Center Boulevard, Suite 177,
Phoenix, AZ 85040, 602-438-8507/800-279-0027;
Sparrow Health System, Toxicology Testing Center, St. Lawrence
Campus, 1210 W. Saginaw, Lansing, MI 48915, 517-364-7400 (Formerly: St.
Lawrence Hospital & Healthcare System);
St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St.,
Oklahoma City, OK 73101, 405-272-7052;
Toxicology & Drug Monitoring Laboratory, University of Missouri
Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO
65203, 573-882-1273;
Toxicology Testing Service, Inc., 5426 NW., 79th Ave., Miami, FL
33166, 305-593-2260;
U.S. Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson
St., Fort George G. Meade, MD 20755-5235, 301-677-7085;
* The Standards Council of Canada (SCC) voted to end its Laboratory
Accreditation Program for Substance Abuse (LAPSA) effective May 12,
1998. Laboratories certified through that program were accredited to
conduct forensic urine drug testing as required by U.S. Department of
Transportation (DOT) regulations. As of that date, the certification of
those accredited Canadian laboratories will continue under DOT
authority. The responsibility for conducting quarterly performance
testing plus periodic on-site inspections of those LAPSA-accredited
laboratories was transferred to the U.S. HHS, with the HHS' NLCP
contractor continuing to have an active role in the performance testing
and laboratory inspection processes. Other Canadian laboratories
wishing to be considered for the NLCP may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to be qualified, HHS will
recommend that DOT certify the laboratory (Federal Register, July 16,
1996) as meeting the minimum standards of the Mandatory
[[Page 369]]
Guidelines published in the Federal Register on April 13, 2004 (69 FR
19644). After receiving DOT certification, the laboratory will be
included in the monthly list of HHS certified laboratories and
participate in the NLCP certification maintenance program.
Pat Bransford,
Acting Executive Officer, SAMHSA.
[FR Doc. 05-3 Filed 1-3-05; 8:45 am]
BILLING CODE 4160-20-P
